A Novel Class of Small Molecule Inhibitors of Hsp90
- 12 September 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 3 (10) , 645-654
- https://doi.org/10.1021/cb800162x
Abstract
Unregulated cellular proliferation, caused by mutation or dysregulation of growth-promoting proteins, is an underlying cause of cancer. Many such growth-promoting proteins exhibit an increased dependence on the activity of the chaperone heat-shock protein 90 (Hsp90) for correct folding and maturation in the cell. One can therefore envision that inhibition of Hsp90 would be an effective and broadly applicable strategy for the development of anticancer agents. Hsp90 functions in multichaperone complexes driven by the binding and hydrolysis of ATP. Encouraging results have been obtained by inhibiting Hsp90 with 17-AAG, an active-site binding ATP analog. Here we present the results of a different approach to inhibiting Hsp90 by disrupting its interaction with a cochaperone named Hsp organizing protein (HOP). We have used an AlphaScreen technology based high-throughput in vitro screen to identify compounds that inhibit this interaction. In addition, we demonstrate that these compounds are active in vivo. Treatment of human breast cancer cell lines BT474 and SKBR3 with these compounds decreases the levels of the Hsp90-dependent client protein HER2, with associated cell death.Keywords
This publication has 26 references indexed in Scilit:
- Structural Studies on the Co-chaperone Hop and Its Complexes with Hsp90Journal of Molecular Biology, 2008
- Designed TPR Modules as Novel Anticancer AgentsACS Chemical Biology, 2008
- Inhibitors of the heat shock response: Biology and pharmacologyFEBS Letters, 2007
- Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced CancerClinical Cancer Research, 2007
- Hot-spot mimicry of a cytokine receptor by a small moleculeProceedings of the National Academy of Sciences, 2006
- A detergent-based assay for the detection of promiscuous inhibitorsNature Protocols, 2006
- Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced MalignanciesJournal of Clinical Oncology, 2005
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- A convenient synthesis of toxoflavins, toxoflavin 4-oxides and 1-demethyltoxoflavins.CHEMICAL & PHARMACEUTICAL BULLETIN, 1975
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973